Aspira Women's Health

In Season 2, Episode 5 of BioBytes, a podcast that features leading innovators in biotech and pharma, our President, Sandy Milligan, MD JD, joins host Shakir Bux, CEO of Windsor Bux, to share her inspiring journey in the pharma industry. She discusses key career moves, the importance of adaptable leadership, and the value of building strong teams. Sandy also offers expert insights on driving innovation in both big pharma and biotech, along with tips on successful regulatory operations. Don’t miss the valuable lessons and insights from her extensive experience in the industry.   YouTube: https://lnkd.in/dshAN4_M Spotify: https://lnkd.in/d4x89Ps2   #AspiraWomensHealth #Biotech #Pharma, #Csuite #Executive #Leadership #innovation #teambuilding #regulatoryaffairs #podcast #womenshealth

Dorsata believes that the tools providers use to document patient data should be designed and built for purpose. Clean and structured data makes it easier for providers to review patient data while driving more intelligent and accurate clinical and administrative decision support. Our partnership with Aspira Women's Health represents another major step towards Dorsata’s vision of a comprehensive platform for women’s health! Thanks to Nicole Sandford and Matt Ramey for making it happen!

S2 Ep 5. Sandy Milligan, MD JD, C-Suite Executive & Board Member. President at Aspira Women's Health Snapshot of a great interview with Sandy who sits with Shakir Bux. In this episode of BioBytes, host Shakir Bux interviews Sandy Milligan, a dynamic and accomplished C-suite executive in the pharma industry. Sandy shares her background and key career moves that have led to her success. They discuss the characteristics of successful leaders in biotech, the importance of building a strong team, and the differences between driving innovation in big pharma versus biotech. Sandy also shares advice she has received throughout her career and the challenges she has faced as a leader in the pharma world. The conversation concludes with a discussion on the key aspects of running a successful regulatory operation in biotech. Takeaways Successful leaders in biotech are adaptable and able to change their management style depending on the life cycle phase of the company. Building a strong team and finding successors is crucial for career growth and advancement. Regulatory affairs should have a seat at the strategic table and work closely with clinical development to develop a strong regulatory strategy. Chapters 00:00 Introduction and Background 04:41 Building Strong Teams and Finding Successors 07:04 Driving Innovation in Big Pharma vs Biotech 17:53 Challenges and Setbacks in Leadership 20:43 Running a Successful Regulatory Operation in Biotech Links posted to listen to the full interview on YouTube or Spotify below and in the comments. Youtube link:  https://lnkd.in/d4DUkmSb Spotify link: https://lnkd.in/dTQ7qBTK #pharmaindustry, #Csuite #executive, #biotech, #leadership, #innovation, #teambuilding, #regulatoryaffairs

Thank-you Shakir for this conversation! Such a pleasure to connect with you. Your global viewpoint and experience is superb and drives to innovative perspectives and outcomes for your clients!

Fast Company published our new article looking at the major innovations happening in health care, from shelving the speculum (a tool invented almost 200 years ago and tested on enslaved women without consent) to reimagining surgical treatments. We look at the three ways healthcare is being impacted by women demanding equity in care: ✨ Proactive vs reactive care ✨ Empower vs disempowered care ✨ Completely reimagined vs incrementally redesigned solutions Read the full article here: https://lnkd.in/gbtPEHGH And meet this amazing companies: iSono Health , Namida Lab, Inc., Nesa Medtech, Aspira Women's Health, Medicines360, Pregnolia AG, Novocuff, Inc., Dionysus Digital Health, Afynia Laboratories, Endometrics, Proov, Evvy, Hyivy Health, HappySneeze, Thyia, Curiva

Breaking News: Aspira Women's Health announces partnership with Dorsata to develop an innovative adnexal mass protocol workflow tool. This innovative new tool will: - Offer the module integrated to Dorsata's platform at over 300 clinical sites - Serve more than 2,500 clinical users - Improve consistency in patient care - Aggregate valuable clinical data nationwide This collaboration aims to enhance diagnosis, treatment, and care for patients with adnexal masses. Read more: https://lnkd.in/eJsUfnEJ   #AspiraWomensHealth #PR #WomensHealth #MedTech #HealthcareInnovation

Discover how our approach helps determine the best course of action for pelvic masses identified on ultrasound. From evaluating risks to considering surgical options, Aspira Women's Health can help you enhance your clinical triage process for pelvic masses and ovarian care.   We’d love to connect with you! Discover how we can seamlessly integrate our suite of non-invasive risk assessment tools into your practice. Reach out to us here for more information: https://lnkd.in/e97K3dTv   #OvarianCancerAwareness #OBGYN #OvarianCancer #OvaWatch #Ova1 #OvaSuite #AspiraWomensHealth #WomensHealth #PelvicMass

Introducing the latest "OvaView" summary with Victoria Haverbusch, our expert in risk assessment. In this brief video, Victoria simplifies the complexities of managing adnexal masses and highlights how Aspira Women's Health is revolutionizing care with our non-invasive tool, OvaWatch. This innovative solution enables providers to offer ongoing, point-in-time, personalized ovarian cancer risk assessments for patients under active surveillance or watchful waiting for their adnexal mass. Discover the latest advancements in biomarker technology for ovarian cancer risk assessment and gain valuable insights to support your clinical decision-making. Watch more OvaView videos here: https://lnkd.in/dTBm3zry #OvaView #AspiraWomensHealth #OvarianCancerAwareness #OvarianCancer #WomensHealth #OvaWatch

ICYMI: Aspira Women's Health recently reported our Q2 2024 Financial Results with highlights including $2.4 million in OvaSuite℠ revenue, 6,471 units in volume, and a 16% decrease in cash utilization compared to Q1 2024. Our full-year cash guidance is now $13-$14.5 million. Missed our call? Catch the replay to get the latest updates on our progress. For more details, check out our full press release here: https://lnkd.in/exsv4c3A #WomensHealth #OvarianCancer #AspiraWomensHealth #PR #InvestorUpdates

Don’t miss our second quarter earnings! Join us today at 4:30 p.m. ET for a conference call where we'll discuss financial results and provide a corporate update. A webcast replay will also be available on the Events & Presentation page of our Investor Relations website. Dial 877-407-4018 or access the webcast here: https://lnkd.in/dQC_xfcg #AspiraWomensHealth #EarningsCall #CorporateUpdate #Q2